Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Larry Brubaker who wrote (6137)	1/16/2000 2:24:00 PM
From: DanZ	Respond to of 10293

Larry, <My reaction was that a drug that can kill the common cold would certainly be a threat to a homeopathic remedy that allegedly reduces symptoms from the common cold.> You might want to do some more research on Pleconaril and the common cold. Viropharma has said that it reduces the duration of the common cold from an average of 14 days to 10 days. The initial study on Zicam indicates that it reduces the duration of the common cold from 14 days to 1.5 days. If you think that Pleconaril "kills the common cold" (which I disagree with), then how would you define a product that purportedly works better than that? Of course the independent clinical studies need to be published before many of the skeptics here will believe that it works, but the stock won't wait for that because enough investors think that it works, and more importantly, Zicam is selling very well because consumers are finding that it works. The homeopathic designation is a labeling issue, as has been discussed here numerous times, and has nothing to do with the efficacy of the product. Generalizations often lead people to the wrong conclusions. Best regards, Dan